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Abstract
Background: Osteogenesis imperfecta (OI) is a congenital disorder characterized by increased bone fragility and
low bone mass.
Methods: The presence of COL1A1 or COL1A2 mutation was investigated by direct sequencing in 72 patients with
OI type I, III, or IV (27 males and 45 females; age range 0.2-62 years) from 37 unrelated families. The clinical features
of these patients were also recorded.
Results: Thirty-seven COL1A1 and COL1A2 mutations were identified, including 28 COL1A1 mutations and 9 COL1A2
mutations. Fifteen (41 %) were novel mutations, and twelve (32 %) were familial mutations. A review of their
medical records revealed that the 72 patients could be classified into OI type I (n = 42), III (n = 5), and IV (n = 25).
Twenty-nine patients had helical mutations (caused by the substitution of a glycine within the Gly-X-Y triplet
domain of the triple helix), and 42 had haploinsufficiency mutations (caused by frameshift, nonsense, and splice-site
mutations). Compared with haploinsufficiency, the patients with helical mutations had more severely impaired
skeletal phenotypes, including shorter height, lower bone mineral density, poorer walking ability, more frequent
manifestations of dentinogenesis imperfecta and scoliosis (p < 0.05).
Conclusions: Genotype and phenotype databases are expected to promote better genetic counseling and medical
care of patients with OI.
Keywords: Bone mineral density, Genotype, Height, Osteogenesis imperfecta, Phenotype
Background
Osteogenesis imperfecta (OI) (MIM# 166200, 166210,
259420, and 166220) is a hereditary disease characterized
by increased bone fragility, low bone mass, short stature,
and other connective tissue manifestations, with a re-
ported incidence of 1:15,000-1:25,000 [1, 2]. Additional
extra-skeletal features manifest to a variable degree, in-
cluding blue sclera, dentinogenesis imperfecta (DI), and
hearing loss [3, 4]. In Western populations, OI is generally
inherited in an autosomal dominant manner, however, a
small number of families inherit their OI in an autosomal
recessive pattern [3]. The most commonly used classifica-
tion is that proposed by Sillence et al. [5], but as modified
and expanded by the International Nomenclature
Committee for Constitutional Disorders of the skeleton as
reported by van Dijk and Sillence 2014 [3] which classifies
OI into five major groups of disorders as types 1–5. Type
I is usually the mildest form, with normal or near-normal
growth and minimal bone deformities. Type II is lethal in
the perinatal period, with multiple intrauterine fractures
and bone deformities of the extremities. Type III is the
most severe form in children who survive the neonatal
period, with fractures often presenting at birth. These
children have extremely short stature with progressive
limb and spine deformities secondary to multiple frac-
tures. Type IV is the most phenotypically heterogeneous
group, with mild to moderate bone deformities and
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variable short stature. In 2012, van Dijk et al. [6] reporting
for the committee on best practice guidelines for diagnosis
and investigation noted 8 types of OI based on clinical
characteristics and molecular genetic defects. However,
OMIM now records 17 OI types and a further 3 syndromic
forms of OI have been defined at the molecular level, 2
types with craniosynostosis/skull deformity and one type
with significant eye involvement.
To date, more than 1,000 different COL1A1/COL1A2
mutations have been identified in patients with OI
(https://oi.gene.le.ac.uk, accessed July 20, 2015). There
are two general categories of type I collagen mutations
giving rise to OI types I to IV. The first are haploinsuffi-
ciency mutations caused by frameshift, nonsense, and
splice-site mutations, which lead to failure to synthesize
the products of one COL1A1 allele. The second involves
the synthesis of collagen molecules with structural ab-
normalities, most frequently caused by the substitution
of glycine by another amino acid in the Gly-X-Y triplet
domain of the triple helix. Previous studies have re-
ported that OI patients with COL1A1 haploinsufficiency
mutations have milder bone fragility and damage than
those with COL1A1/COL1A2 helical glycine mutations
[7, 8]. Both COL1A1 and COL1A2 genes are very large,
and they have rarely been analyzed systematically in
Taiwan. The aim of this study was to characterize the
correlations of genotype and phenotype for Taiwanese
OI patients, with the hope that this may aid in the
clinical diagnosis, genetic counseling and prenatal
diagnosis of this disease.
Patients and methods
Study population
Seventy-two Taiwanese patients (27 males and 45 females;
age range at last follow-up, 0.2-62 years) from 37 unre-
lated families were diagnosed with OI during the study
period (January 1996 through December 2014) at Mackay
Memorial Hospital, Taipei, Taiwan. None of the patients
belonged to a consanguineous family. Molecular analysis
was performed to investigate the presence of COL1A1 or
COL1A2 mutations. This is an analysis of only those
patients found to have a molecular genetic finding of a
mutation in one of the two type I collagen genes. Clinical
manifestations and the results of physical examinations
and imaging studies of these patients were also recorded.
The hospital’s Ethics Committee approved the study
protocol, and all of the participants or their parents pro-
vided written informed consent.
Clinical assessment
Diagnosis and classification were based on clinical and
radiological characteristics according to the Sillence clas-
sification system [5]. In this study, every patient was
evaluated at our clinic by one author, in person, to
minimize inter-observer variation. For each patient, we
recorded their height, weight, and bone mineral density
(BMD) standard deviation scores (SDSs), walking ability
and family history, and the occurrence of blue sclera, DI,
hearing loss, bone deformity, and scoliosis. Height and
weight were transformed to SDSs on the basis of a
standard growth table for Taiwanese children and
adolescents [9]. The BMD of the lumbar spine (L1–L4)
was assessed using dual energy X-ray absorptiometry
(DEXA) with a Hologic QDR 4500 system (Hologic,
Bedford, MA, USA) [4]. The BMD results were con-
verted to age- and gender-specific SDSs based on the
normative reference data for BMD in Taiwanese children
and adults [10, 11]. Pamidronate therapy has been re-
ported to increase BMD, decrease the fracture rate, and
substantially improve functional status for OI patients
[12]. However, none of our patients had received pami-
dronate treatment at the time of assessment.
Mutation analysis for type I collagen
Total genomic DNA was isolated from peripheral blood
using standard extraction methods. DNA sequencing of
all 51 polymerase chain reaction-amplified exons of the
COL1A1 gene and 52 exons of the COL1A2 gene, in-
cluding the intron-exon boundaries, was performed
using a BigDye Terminator cycle sequencing kit (Applied
Biosystems, Foster City, CA, USA). The nucleotide se-
quence was determined using an Applied Biosystems
3100 DNA sequencer. Sequence traces were aligned with
the GenBank reference sequences of COL1A1 genomic
DNA (AF017178.2) and cDNA (NM_000088.3), and
COL1A2 genomic DNA (AF004877.1) and cDNA
(NM_000089.3). DNA mutation numbering was based
on the cDNA sequence using the A of the ATG transla-
tion initiation start site as nucleotide +1. Novel muta-
tions were identified by their absence from the
Osteogenesis Imperfecta Variant Database (https://
oi.gene.le.ac.uk/home.php). In addition, identified nu-
cleotide changes were re-examined in 100 control alleles.
Polymorphisms were considered if the same nucleotide
changes were detected in the control group.
Statistical analysis
Relationships between gender, age, BMD SDS, DI and
the existence of each clinical feature in the OI patients
were tested using Pearson correlation, and significance
was tested using Fisher r-z transformations. The clinical
and radiological data were compared between patients with
helical mutations versus those with haploinsufficiency
mutations using the Student’s t-test for continuous variable,
and Pearson’s chi-squared test and Fisher’s exact test for
categorical variables. Two-tailed p-values were computed.
SPSS version 11.5 (SPSS Inc., Chicago, IL) was used for
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calculations and differences were considered to be statisti-
cally significant when the p value was less than 0.05.
Results
Clinical characteristics
A review of the patients’ medical records revealed that
among the 72 OI patients, 42 (58 %) were classified as
OI type I, 5 (7 %) as type III, and 25 (35 %) as type IV.
None of the patients had OI type II. The SDSs for
height, weight, and BMD for all patients were–1.61 ±
2.57,–0.84 ± 1.56, and–2.06 ± 1.62, respectively. Further-
more, when dividing the patients into groups by OI type,
the height SDSs were–0.49 ± 1.37,–6.42 ± 5.54, and–2.51
± 1.85, respectively; and the BMD SDSs were–1.57 ±
1.15,–3.32 ± 1.86, and − 2.69 ± 1.96, respectively, for type
I, III, and IV. A triangular face, blue sclera, DI, hearing
loss, bone deformity, scoliosis, and walking without as-
sistance were recorded in 18, 89, 43, 19, 58, 36 and 90 %
of the patients, respectively. An older age was associated
with hearing loss (p < 0.01). The BMD SDS was posi-
tively correlated with the ability to walk without assist-
ance (p < 0.01). Patients with DI appeared to be prone
to developing bone deformities (p < 0.01) and scoliosis
(p < 0.01). Girls with OI had a slightly higher BMD
SDS than boys with the same mutation type (p < 0.05)
(Additional file 1: Table S1 and Additional file 2: Table S2).
COL1A1 and COL1A2 mutations
Thirty-seven COL1A1 and COL1A2 mutations were
identified in the 72 patients, including 28 COL1A1
mutations and 9 COL1A2 mutations. None of the
COL1A1 or COL1A2 mutations were the same among
these 37 unrelated families, and 15 (41 %) were novel
mutations. Among the 28 COL1A1 mutations, 7 were
missense mutations, 4 were nonsense mutations, 6 were
splicing mutations, and 11 were frameshift mutations.
Eight familial mutations were identified. All 9 COL1A2
mutations were missense mutations, 4 of which were
from familial inheritance (Tables 1 and 2). Among the
37 causative COL1A1 and COL1A2 mutations, 15 (41 %)
were caused by the substitution of a glycine within the
Gly-X-Y triplet domain of the triple helix. There were 7
glycine mutations in COL1A1 and 8 in COL1A2. Among
the 15 glycine mutations, aspartic acid substitutions
were the most common type (n = 6, 40 %), followed
by serine (n = 4, 27 %), arginine (n = 2, 13 %), cysteine
(n = 2, 13 %), and glutamic acid (n = 1, 7 %) substitu-
tions. Of the 21 haploinsufficiency mutations in
COL1A1, 11 were frameshift mutations, 6 were spli-
cing mutations, and 4 were nonsense mutations.
Genotype and phenotype analysis
The OI type was correlated with mutated genes and muta-
tion types. Compared with COL1A2 mutations, COL1A1
mutations were more frequent in the patients with OI
type I (46 % vs. 33 %) and III (14 % vs. 11 %), and less
frequent in the patients with OI type IV (39 % vs. 56 %).
Helical mutations were more frequent in the patients with
OI type III (27 % vs. 5 %) and IV (47 % vs. 38 %), and less
frequent in the patients with OI type I (27 % vs. 57 %)
compared to those with haploinsufficiency mutations
(Table 3). Among the 72 patients, 51 had a COL1A1 muta-
tion and 21 had a COL1A2 mutation. Twenty-nine patients
had helical mutations and 42 had haploinsufficiency muta-
tions. Compared with haploinsufficiency, the patients with
helical mutations had more severely damaged skeletal
phenotypes, including shorter height, lower weight and
BMD, poorer walking ability, and more frequent manifesta-
tions of DI and scoliosis (p < 0.05) (Table 4, Fig: 1a and b).
Discussion
A number of studies have described the clinical and mo-
lecular findings for Western patients with OI [13–17];
however, only a few studies have been conducted in
Asian patients [8, 18, 19]. To the best of our knowledge,
this is the first large-scale study to analyze the genotypes
and phenotypes of Taiwanese patients with OI. We
identified 37 different COL1A1/COL1A2 mutations in
72 patients from 37 unrelated families, including 28
COL1A1 mutations and 9 COL1A2 mutations. Among
these 37 COL1A1/COL1A2 mutations, 16 (43 %) were
missense mutations, 11 (30 %) were frameshift muta-
tions, 6 (16 %) were splicing mutations, and 4 (11 %)
were nonsense mutations. These mutations were unique
and were not repeated between the families, meaning
that there was no hot-spot COL1A1/COL1A2 mutation
in the study population. Fifteen (41 %) of the mutations
were novel and 12 (32 %) were familial. In Zhang et al’s
study [8], 19 of 58 (33 %) Chinese patients had familial
OI, and Venturi et al. [17] reported that 7 of 22 (32 %)
Italian OI patients were familial cases, both of which are
consistent with our results. However, Lee et al. [18] de-
scribed a higher incidence of familial OI with 18 of 34
(53 %) Korean patients. Further studies are needed to
elucidate whether this is an artifactual difference related
to a limitation in sample size or whether there are ethnic
differences in the genetic defects underlying OI. Similar
to previous population studies on OI in other countries
[8, 14–19], most of our Taiwanese OI patients were cate-
gorized into type I (58 %), followed by type IV (35 %)
and type III (7 %). In addition, none of the patients had
OI type II in this study.
Growth retardation is a notable symptom of OI, and it
is extremely severe in patients with OI type III. Moriwake
and Seino [20] reported a national survey of Japanese OI
patients with height SDSs of −3.36 ± 3.59,−7.83 ± 3.54,
and − 4.63 ± 3.13 in patients with OI type I, III and IV,
respectively, which is consistent with our findings.
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F29 I Exon 8 c.335G > A p. Gly112Asp Missense Helical Yes F
F30 IV Exon 24 c.1378G > A p. Gly460Ser Missense Helical S
F31 IV Exon 29 c.1666G > T p. Gly556Cys Missense Helical Yes S
F32 IV Exon 33 c.2018G > A p. Gly673Asp Missense Helical S
F33 I Exon 37 c.2197G > T p. Gly733Cys Missense Helical F
F34 IV Exon 37 c.2279G > A p. Gly760Glu Missense Helical F
F35 III Exon 37 c.2288G > A p. Gly763Asp Missense Helical S
F36 I Exon 40 c.2531G > A p. Gly844Asp Missense Helical Yes F
F37 IV Exon 51 c.3815G > C p. Cys1272Ser Missense - Yes S
OI osteogenesis imperfecta



















F1 I Exon 4 c.333-9A > G Splicing Haploinsufficiency Yes S
F2 I Exon 5 c.441delC Frameshift Haploinsufficiency S
F3 I Exon 5 c.386_387insC Frameshift Haploinsufficiency Yes F
F4 IV Exon 5 c.391C > T p. Arg131X Nonsense Haploinsufficiency S
F5 IV Exon 6 c.477_478 insT Frameshift Haploinsufficiency Yes S
F6 I Exon 7 c.579delT p. Pro193Profs*72 Frameshift Haploinsufficiency F
F7 IV Exon 8 c.642 + 1G > A Splicing Haploinsufficiency S
F8 I Exon 8 c.590G > A p. Gly197Asp Missense Helical S
F9 I Exon 9 c.658C > T p. Arg220X Nonsense Haploinsufficiency F
F10 IV Exon 11 c.769G > A p. Gly257Arg Missense Helical F
F11 IV Intron 12 c.858 + 24G > A Splicing Haploinsufficiency Yes S
F12 III Exon 13 c.878G > A p. Gly293Asp Missense Helical Yes S
F13 III Exon 16 c.1021G > C p. Gly341Arg Missense Helical Yes S
F14 IV Intron 17 c.1155 + 3_1155 +
6del
c.1155 + 3_6delAAGT Splicing Haploinsufficiency S
F15 I Intron 20 c.1354-12G > A Splicing Haploinsufficiency F
F16 I Exon 21 c.1380delT Frameshift Haploinsufficiency F
F17 IV Exon 24 c.1667delC Frameshift Haploinsufficiency Yes S
F18 I Exon 24 c.1615-1G > T Splicing Haploinsufficiency Yes S
F19 IV Exon 35 c.2384-2394 del 11
mers
Frameshift Haploinsufficiency Yes S
F20 IV Exon 36 c.2461G > A p. Gly821Ser Missense Helical S
F21 I Exon 37 c.2523delT Frameshift Haploinsufficiency S
F22 I Exon 38 c.2644C > T p. Arg882X Nonsense Haploinsufficiency F
F23 I Exon 40 c.2775delT Frameshift Haploinsufficiency Yes S
F24 III Exon 42 c.3064G > A p. Gly1022Ser Missense Helical S
F25 I Exon 42 c.3076C > T p. Arg1026X Nonsense Haploinsufficiency F
F26 IV Exon 44 c.3124_3134del11 Frameshift Haploinsufficiency Yes S
F27 IV Exon 47 c.3505G > A p. Gly1169Ser Missense Helical S
F28 III Exon 52 c.4308_4309insA Frameshift Haploinsufficiency S
OI osteogenesis imperfecta
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Patients with OI have a significantly lower BMD.
DEXA can detect a low BMD that may be missed on
plain radiographs, even in patients with the milder forms
of OI [21]. It may therefore aid in establishing the diag-
nosis, assessing the prognosis, and possibly monitoring
the response to medical treatment. Among the 65
patients with available DEXA data of BMD in the present
study, 94 % had a reduced BMD, 48 % with BMD SDS <
−2, and 31 % with BMD SDS < −1 and ≧ − 2.
Blue sclera is a distinctive feature of unknown etiology
in OI, and most patients with OI type I have blue sclera
throughout their lives. In OI type III and IV, the sclera
may also be blue at birth and during infancy, however
the blue color fades with time during childhood [22].
The majority of our patients (89 %) had blue sclera.
DI is another principle manifestation of OI, and is
associated with an abnormal type I collagen molecule.
Discoloration and pulpal obliteration are the major
characteristics. Lukinmaa et al. [23] reported that DI is
frequently observed in OI type III and IV, but not
commonly in type I. Our results were consistent with
this finding, and 80 % of the OI type III patients had DI,
followed by 56 % of the type IV patients and 31 % of the
type I patients. We also found that the patients with DI
appeared to be prone to developing bone deformities
(p < 0.01) and scoliosis (p < 0.01).
Progressive hearing loss is an important symptom of
OI, with the most common age at onset being in the sec-
ond to fourth decades of life [24]. In our study, 19 % of
the patients had hearing loss at a mean age of 39.1 years
compared to 17.5 years without hearing loss, and an in-
crease in age was associated with the presence of hearing
loss (p < 0.01).
In patients with OI, the causes of bone deformities in-
clude an imperfect healing process after a fracture, and
weight bearing itself without an apparent fracture. Bone
deformities are frequently observed in the long bones,
and scoliosis, spinal deformities, and compression frac-
tures are also commonly seen [20]. In our study, 58 % of
the patients presented with bone deformities.
The pathology of scoliosis is based on vertebral fragility,
which progressively deteriorates with age [25]. Karbowski
et al. [26] performed a nationwide cross-sectional study
on German patients with OI, and reported that scoliosis
was observed in 74.5 % (76/102) of their patients with an
average age of 24.6 years. In our patients, 36 % (26/72)
had scoliosis with a mean age of 27.3 years.
Rauch et al. [7] reported that girls with OI have a
slightly higher BMD than boys with the same mutation
type. Their histomorphometric observations also showed
that bone formation and turnover rates were lower in
Table 4 Relationship between clinical characteristics and different mutation types (helical mutation vs. haploinsufficiency) in COL1A1
and COL1A2 of 71 patients with OI at the time of bone densitometry analysis
Helical mutation (n = 29) Haploinsufficiency (n = 42) p value
OI Type (I/III/IV) 9/4/16 33/1/8 <0.001
COL1A1/COL1A2 mutation 9/20 42/0 <0.001
Gender (M/F) 12/17 15/27 0.635
Age (years) 21.8 ± 17.1 21.4 ± 17.0 0.941
Height SDS −2.93 ± 3.04 −0.61 ± 1.61 <0.001
Weight SDS −1.29 ± 1.67 −0.55 ± 1.44 <0.05
BMD SDS −2.73 ± 1.96 (n = 24) −1.70 ± 1.25 (n = 40) <0.05
Triangular face 21 % 17 % 0.672
Blue sclera 83 % 95 % 0.085
Dentinogenesis imperfecta 62 % 31 % <0.01
Hearing loss 17 % 21 % 0.668
Fracture at birth 14 % 5 % 0.184
Bone deformity 69 % 50 % 0.115
Scoliosis 52 % 26 % <0.05
Walking without assistance 76 % (n = 25) 98 % <0.01
OI osteogenesis imperfecta, SDS standard deviation score, BMD bone mineral density






COL1A1 (n = 28) 13 (46 %) 4 (14 %) 11 (39 %)
COL1A2 (n = 9) 3 (33 %) 1 (11 %) 5 (56 %)
Helical mutation (n = 15) 4 (27 %) 4 (27 %) 7 (47 %)
Haploinsufficiency (n = 21) 12 (57 %) 1 (5 %) 8 (38 %)
OI osteogenesis imperfecta
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girls than in boys. Lower bone turnover is expected to
result in a slightly higher bone mass. The same results
were also observed in our study.
There is a tendency to give more weighting to severity
in phenotypic grouping whereas recent reviews stress
that there is variability in severity encompassing mild to
moderate phenotypes within families in patients with
both OI type 1 and type 4 [3]. The persistence of deep
blue-gray scleral hue should be given more weighting in
favor of OI type 1 in families although scleral hue is
difficult to assess in small children with OI type 4 who
may have quite marked blue-gray sclera in infancy which
subsequently fade to white in later childhood [22].
In our study cohort of Taiwanese OI patients, COL1A1
mutations occurred 3.1 times (28:9) more frequently
than COL1A2 mutations, and the replacement of glycine
residues by other residues within the Gly-X-Y triplet do-
main of the triple helix in both COL1A1 and COL1A2
was common. Our results are consistent with those of a
previous study on Chinese patients [8]. Of the 15 glycine
mutations, 6 (40 %) had glycine-to-aspartic acid substi-
tutions, which is higher than previously reported in a
mutation database (7.4 % in COL1A1 and 15.8 % in
COL1A2) [27]. The mutation database also reported that
serine substitutions were the most common type of
mutation in both COL1A1 (38.9 %) and COL1A2 (44 %)
[27], however, only 4 (27 %) serine substitutions were
identified in our sample.
We found that the OI type was correlated with
mutated genes and mutation types. Rauch et al. [7] and
Zhang et al. [8] both reported that compared with
COL1A2 mutations, COL1A1 mutations were more
frequent in patients with OI type I and less frequent in
those with OI type IV. Compared with haploinsuffi-
ciency mutations, helical mutations occurred more com-
monly in the patients with OI type III and IV, and less
commonly in the patients with OI type I. Although the
Sillence classification is based exclusively on phenotypic
criteria and is inevitably used inconsistently among dif-
ferent OI investigators, our results were still similar to
previous reports [7, 8].
COL1A1 haploinsufficiency mutations result in a
quantitative defect, with synthesis of structurally normal
type I procollagen at about half of the normal amount.
Fig. 1 Relationships between age and a height SDS (n = 71), b BMD SDS (n = 64) of different mutation types [COL1A1/COL1A2 helical glycine
mutation (blue dot) vs. COL1A1 haploinsufficiency mutation (pink dot)] in patients with osteogenesis imperfecta. SDS, standard deviation score;
BMD, bone mineral density
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They initiate nonsense-mediated decay of the mRNA
derived from that allele leading to mild bone fragility.
COL1A1/COL1A2 helical glycine mutations cause the
synthesis of collagen molecules with structural abnor-
malities, which can result in a clinical severity from mild
OI type I to lethal OI type II. Previous studies have re-
ported that OI patients with COL1A1 haploinsufficiency
mutations have milder bone fragility and damage than
those with COL1A1/COL1A2 helical glycine mutations
[7, 8, 27], and this is consistent with our results.
Limitations
Due to the limited sample size in this single-center
retrospective study, substitutions by many amino acid
residues as well as the position of a mutation occurred
too infrequently to draw any conclusions about their
phenotypic effects. In addition, our results were limited
to BMD of the lumbar spine, which may not be repre-
sentative of other skeletal involvement, especially the ap-
pendicular skeleton. The small sample size also reflects
the rare nature of this genetic disorder, and both the age
range and degree of disease severity varied widely.
Therefore, further multicenter studies with larger
cohorts and a longer follow-up period are warranted.
Conclusion
Thirty-seven mutations were identified in the COL1A1/
COL1A2 genes and were associated with OI type I, III
and IV by direct sequencing in our Taiwanese patients,
including 28 COL1A1 mutations and 9 COL1A2 muta-
tions. Among them, 15 (41 %) were novel mutations, 12
(32 %) were familial mutations, and 15 (41 %) were caused
by the substitution of a glycine within the Gly-X-Y triplet
domain of the triple helix. Patients with COL1A1/COL1A2
helical glycine mutations had more severely damaged skel-
etal phenotypes than those with COL1A1 haploinsufficiency
mutations. Genotype and phenotype databases are expected
to promote better genetic counseling and medical care of
patients with OI.
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